← All trials
NCT06413498
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 23, 2024
- Primary completion
- Jul 31, 2028
- Completion date
- Jul 31, 2031
- First posted
- May 14, 2024
- Last posted
- Oct 16, 2024
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gilead SciencesLead sponsor
- Gilead SciencesOfficial
- Arcellx, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.